Abiopharma

🔍 Singh Jesse G (Executive)

Company: Fortune Brands Innovations, Inc. (FBIN)

Report Date: 2026-08-06

Detailed Transactions and Holdings:

• Acquired 14,444 shares of Common Stock, Par Value $0.01 at $51.4576 per share (Direct)
  Date: 2026-08-06 | Code: P | equity_swap_involved: false | shares_owned_after: 14,444.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 5,281 shares of Common Stock, Par Value $0.01 at $52.2301 per share (Direct)
  Date: 2026-08-06 | Code: P | equity_swap_involved: false | shares_owned_after: 19,725.00 | transaction_form_type: 4 | Footnotes: F2
• Acquired 19,560 shares of Common Stock, Par Value $0.01 at $50.9336 per share (Direct)
  Date: 2026-08-07 | Code: P | equity_swap_involved: false | shares_owned_after: 39,285.00 | transaction_form_type: 4 | Footnotes: F3

Footnotes:

• F1: The price reported is the weighted average price. The shares were purchased in multiple transactions at prices ranging from $50.91 to $51.90, inclusive. The reporting person undertakes to provide to the SEC, the issuer and any security holder full information regarding the number of shares and the prices at which the shares were purchased.
• F2: The price reported is the weighted average price. The shares were purchased in multiple transactions at prices ranging from $51.98 to $52.53, inclusive. The reporting person undertakes to provide to the SEC, the issuer and any security holder full information regarding the number of shares and the prices at which the shares were purchased.
• F3: The price reported is the weighted average price. The shares were purchased in multiple transactions at prices ranging from $50.64 to $51.18, inclusive. The reporting person undertakes to provide to the SEC, the issuer and any security holder full information regarding the number of shares and the prices at which the shares were purchased.